scispace - formally typeset
S

Sewa S. Legha

Researcher at University of Texas MD Anderson Cancer Center

Publications -  118
Citations -  8123

Sewa S. Legha is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Cancer & Breast cancer. The author has an hindex of 44, co-authored 118 publications receiving 7939 citations. Previous affiliations of Sewa S. Legha include University of Texas Health Science Center at Houston & University of Texas System.

Papers
More filters
Journal ArticleDOI

Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion.

TL;DR: Cutting peak plasma levels of doxorubicin by continuous infusion reduces cardiotoxicity, and thus lessen cardiac toxicity, in patients treated by standard intravenous injection.
Journal Article

Phase I and Pharmacokinetic Study of ABI-007, a Cremophor-free, Protein-stabilized, Nanoparticle Formulation of Paclitaxel

TL;DR: ABI-007 offers several features of clinical interest, including rapid infusion rate, absence of requirement for premedication, and a high paclitaxel MTD, which provides support for Phase II trials to determine the antitumor activity of this drug.
Journal ArticleDOI

Tamoxifen in the Treatment of Breast Cancer

TL;DR: A significant increase in the disease-free survival of postmenopausal women treated with tamoxifen is shown, particularly in patients with hormone-receptor-positive tumors.
Journal ArticleDOI

Sequential Biochemotherapy Versus Chemotherapy for Metastatic Melanoma: Results From a Phase III Randomized Trial

TL;DR: Cytokines substantially augment the antitumor activity of chemotherapy at the expense of considerable toxicity in patients with metastatic melanoma.
Journal ArticleDOI

Treatment of uveal melanoma metastatic to the liver. A review of the M. D. Anderson cancer center experience and prognostic factors

TL;DR: The results of an institutional experience over the past 2 decades are reviewed and prognostic factors that affect survival from the time the liver metastasis is diagnosed are assessed.